A Randomized Trial to Evaluate Efficacy and Safety of Intracavernosal Injection of Platelet-Rich Plasma Versus Phosphodiesterase Type-5 Inhibitors for Treatment of Erectile Dysfunction.

NCT05787769 | Unknown DMC

• 1 other identifier: PRP-ED
• Study Type: interventional
• Target: 96
• Locations: 1 country
• Sites: 1

Brief Summary

The aim of this study is to evaluate the efficacy and safety of intracavernosal injection of PRP in patients with moderate to severe ED.

Conditions

Erectile Dysfunction Following Radiation Therapy; Phosphodiesterase Inhibitor Adverse Reaction; Platelet- Rich Plasma (PRP)

Keywords

Erectile Dysfunction , Phosphodiesterase Inhibitor Adverse Reaction, platelet- rich plasma

Outcome Measures

Primary Outcomes (1)

• efficacy of intracavernosal injections of platelet-rich plasma (PRP) in patients Erectile Dysfunction.

  assessed by the proportion of patients attaining minimal clinically important difference in the international index of erectile function - erection dpmain.

  6 months

Study Arms (2)

P shot arm

ACTIVE COMPARATOR

Drug: Autologous Platelet Rich Plasma + placebo tab Each injection session will consist of a total of 10 mL PRP infused slowly over a 2-minute period; 5 mL each injected to the right and left corpus cavernosum.

Drug: P shot arm ( Autologous Platelet Rich Plasma)

PDE5i arm

ACTIVE COMPARATOR

Drug: Tadalafil + placebo injection Patients will be treated by tadalafil 5 mg tablet daily in addition to four Tadalafil 5 mg tablet 3 hours before intercourse on demand in addition to placebo injection. Each injection session will consist of a total of 10 mL saline solution infused slowly over a 2-minute period; 5 mL each injected to the right and left corpus cavernosum.

Drug: PDE5i arm

Interventions

P shot arm ( Autologous Platelet Rich Plasma) DRUG

Autologous Platelet Rich Plasma + placebo tab Each injection session will consist of a total of 10 mL PRP infused slowly over a 2-minute period; 5 mL each injected to the right and left corpus cavernosum

Also known as: Autologous Platelet Rich Plasma

P shot arm

PDE5i arm DRUG

Patients will be treated by tadalafil 5 mg tablet daily in addition to four Tadalafil 5 mg tablet 3 hours before intercourse on demand in addition to placebo injection. Each injection session will consist of a total of 10 mL saline solution infused slowly over a 2-minute period; 5 mL each injected to the right and left corpus cavernosum.

PDE5i arm

Eligibility Criteria

• Age: 30 Years - 75 Years
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• \) Men between 30 and 75 years old, 4) Sexually active in a stable, heterosexual relationship of at least six months duration.
• \) ED for at least 6 months with an IIEF-EF between 5 and 16 points, inclusive. 6) ED of vascular origin. 7) Subjects agree to attempt vaginal intercourse at least 4 times every month after the end of the treatment and agree to document the outcome using the Sexual Encounter Profile (SEP) and the Erection Hardness Score (EHS).
• \) Commitment not to use other treatment for ED during the study (herbal, topical, intraurethral, intracavernosal, etc.).
• \) Willingness and ability to comply with study procedures, other measurements instruments and visit schedules and able to follow oral and written instructions.

You may not qualify if:

• \) Refuse to complete study requirements. 2) Psychogenic ED as determined by study investigator. 3) ED of neurogenic origin (radical cystectomy, radical prostatectomy, pelvic surgery, spinal cord injury, multiple sclerosis, DM is not included unless documented diabetic neuropathy).
• \) Previous penile surgery of any kind (except circumcision, frenuloplasty and condyloma removal), such as penile prosthesis, penile lengthening, penile cancer surgery, penile plication, grafting.
• \) Previous history of penile fracture, Peyronie's disease or priapism. 6) Previous radiation to pelvis. 7) History of symptomatic hypogonadism (testosterone level \<346ng/dl) not treated.
• \) Major hematologic, renal, or hepatic abnormalities. 9) Severe decompensated cardiac, CNS or vascular insufficiency. 10) Poorly controlled hypertension or DM (HbA1c \>12%). 11) Neoplasm of any origin in active treatment or active progression or recovering from cancer within 12 months prior to enrollment.
• \) History of alcohol abuse or drug. 13) Treatment with oral anticoagulants, antiandrogens or nitrates. 14) Thrombopenia less than 100 x 103 / L. 15) Hemoglobin \<10g/dl. 16) Poor venous access or any other circumstance that preclude an apheresis procedure.
• \) Sexually inactive in recent months. 18) participation in another study that may interfere with the results or conclusions of this study.

Sponsors & Collaborators

• Mansoura University: lead

Study Sites (1)

Mansoura urology and nephrology center

Al Mansurah, Outside U.S./Canada, 35516, Egypt

Location

MeSH Terms

Conditions

Erectile Dysfunction

Condition Hierarchy (Ancestors)

Genital Diseases, Male; Genital Diseases; Urogenital Diseases; Sexual Dysfunction, Physiological; Male Urogenital Diseases; Sexual Dysfunctions, Psychological; Mental Disorders

Study Officials

• Ahmed El-assmy

  Mansoura University

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, INVESTIGATOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: March 15, 2023
• First Posted: March 28, 2023
• Study Start: March 1, 2023
• Primary Completion: January 25, 2025
• Study Completion: January 25, 2025
• Last Updated: March 28, 2023

Record last verified: 2023-03

Locations

EG (1)